Osborne Partners Capital Management’s Invesco Biotechnology & Genome ETF PBE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q4 | – | Sell |
-16,800
| Closed | -$796K | – | 159 |
|
|
2019
Q3 | $796K | Hold |
16,800
| – | – | 0.16% | 93 |
|
|
2019
Q2 | $899K | Hold |
16,800
| – | – | 0.17% | 90 |
|
|
2019
Q1 | $927K | Hold |
16,800
| – | – | 0.18% | 85 |
|
|
2018
Q4 | $791K | Sell |
16,800
-500
| -3% | -$23.5K | 0.12% | 119 |
|
|
2018
Q3 | $1.03M | Sell |
17,300
-120
| -0.7% | -$7.13K | 0.13% | 111 |
|
|
2018
Q2 | $953K | Sell |
17,420
-200
| -1% | -$10.9K | 0.13% | 111 |
|
|
2018
Q1 | $867K | Hold |
17,620
| – | – | 0.12% | 116 |
|
|
2017
Q4 | $831K | Sell |
17,620
-50
| -0.3% | -$2.36K | 0.11% | 121 |
|
|
2017
Q3 | $882K | Hold |
17,670
| – | – | 0.12% | 119 |
|
|
2017
Q2 | $807K | Hold |
17,670
| – | – | 0.11% | 115 |
|
|
2017
Q1 | $747K | Sell |
17,670
-300
| -2% | -$12.7K | 0.11% | 120 |
|
|
2016
Q4 | $697K | Hold |
17,970
| – | – | 0.1% | 124 |
|
|
2016
Q3 | $754K | Hold |
17,970
| – | – | 0.11% | 119 |
|
|
2016
Q2 | $665K | Hold |
17,970
| – | – | 0.1% | 123 |
|
|
2016
Q1 | $688K | Hold |
17,970
| – | – | 0.1% | 120 |
|
|
2015
Q4 | $908K | Hold |
17,970
| – | – | 0.13% | 115 |
|
|
2015
Q3 | $822K | Hold |
17,970
| – | – | 0.12% | 118 |
|
|
2015
Q2 | $1.05M | Hold |
17,970
| – | – | 0.14% | 116 |
|
|
2015
Q1 | $991K | Hold |
17,970
| – | – | 0.13% | 117 |
|
|
2014
Q4 | $902K | Sell |
17,970
-700
| -4% | -$35.1K | 0.11% | 123 |
|
|
2014
Q3 | $863K | Hold |
18,670
| – | – | 0.11% | 118 |
|
|
2014
Q2 | $816K | Hold |
18,670
| – | – | 0.11% | 118 |
|
|
2014
Q1 | $777K | Sell |
18,670
-80
| -0.4% | -$3.33K | 0.1% | 125 |
|
|
2013
Q4 | $695K | Hold |
18,750
| – | – | 0.09% | 126 |
|
|
2013
Q3 | $658K | Hold |
18,750
| – | – | 0.09% | 126 |
|
|
2013
Q2 | $542K | Buy |
+18,750
| New | +$542K | 0.08% | 131 |
|